Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-01
1998-04-28
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, A61K 3800, A61K 3810, A61K 3816
Patent
active
057444455
ABSTRACT:
A method of treating pulmonary disease states, e.g., a disease state selected from the group consisting of: cystic fibrosis, neoplasias, bronchogenic cancers, pneumonia, bronchitis, bronchopulmonary viral infections, and bronchopulmonary microbial infections, comprising delivery of an amphipathic non-naturally occurring peptide to an appropriate corporeal site, e.g., pulmonary and/or gastrointestinal loci, to effectively treat such diseases. In a further specific aspect, the invention contemplates a method of treating cystic fibrosis by delivery of lytic, amphipathic non-naturally occurring peptides to pulmonary loci, thereby effecting treatment of bronchopulmonary microbial infections associated with cystic fibrosis through lysis of pathogenic bacteria. Peptides delivered to a gastrointestinal locus preferably are non-lytic, so as not to affect normal gastrointestinal flora, and preferably are chemically modified to confer enhanced proteolytic resistance for an oral method of delivery. Peptides delivered to a pulmonary locus advantageously exhibit lytic activity and do not require chemical modification for proteolytic resistance. The delivery of the peptide to a pulmonary locus may for example be effected by use of a nebulizer device.
REFERENCES:
patent: 4355104 (1982-10-01), Hultmark et al.
patent: 4520015 (1985-05-01), Hultmark et al.
patent: 4810777 (1989-03-01), Zasloff
patent: 5186166 (1993-02-01), Riggs et al.
patent: 5254535 (1993-10-01), Zasloff et al.
MP Search Abstracts of WO 901 2826, Jaywes (Nov. 1990).
Jaynes, J.M., et al, "In Vitro Cytocidal Effect of Lytic Peptides on Several Transformed Mammalian Cell Lines," Peptide Research, 2: 157-160 (1989).
Jaynes, J. M., "Lytic Peptides Portned an Innovative Age in the Management and Treatment of Human Disease", Drug News and Perspectives, 3: 69-78 (1990).
Akerfeldt, et al., "Synthetic Peptides as Models for Ion Channel Proteins," Acc. Chem. Res., 26: 191-197 (1993).
Collins, F.S., "Cystic Fibrosis: Molecular Biology and Therapeutic Implications," Science 256: 774-779 (1992).
Jaynes, J.M., et al, "In Vitro Effect of Novel Lytic Peptides on Plasmodium Falciparium and Trypanosoma Cruzi," Faseb J. 2: 2878-2883 (1988).
Gorecki, M. et al, "Non Cationic Substrates of Trypsin," Biochem. and Biophys. Res. Comm. 29 (2): 189-193 (1967).
Higgins, C. F., et al, Nature 262: 250-255 (1993).
Wong, W.S.D., et al "Pyridine Borane as a Reducing Agent for Proteins," Anal. Biochem. 139: 58-67 (1984).
Reed, W. A. et al, "Enhanced In Vitro Growth of Murine Fibroblast Cells and Preimplantation Embroyos Cultured in Medium Supplemented with an Amphipathic Peptide," Molecular Reproduction and Development 31: 106-113 (1992).
Arrowood, M. J., et al, "Hemolytic Properties of Lytic Peptides Active Against the Sporozites of Cryptospordium Parvium," J. Protozool. 38: 161s-163s (1991).
Jaynes Jesse M.
Julian Gordon R.
Celsa Bennett
Demeter Biotechnologies, Ltd.
Tsang Cecilia J.
LandOfFree
Method of treating pulmonary disease states with non-naturally o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating pulmonary disease states with non-naturally o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating pulmonary disease states with non-naturally o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532005